Dyslipidemia - Pipeline agents unlikely to rejuvenate the market

At present, despite the availability of numerous agents for the treatment of dyslipidemia, there is significant scope for expanding the market by improving diagnosis and treatment of dyslipidemia patients. However, for new agents, gaining a secure foothold on the market will be challenging, but their chances can be improved through targeting niche patient populations and conducting outcome trials.

Single-pill combinations have their appeal, but not for every market. Their rather low uptake, especially in Europe, is due to a common perception that they are inferior to separate compounds in titration flexibility; as well as their high cost and potentially poor side effect profile. This will limit their success, especially In Europe and Japan.

Increased efficacy in HDL-C raising is the most important unmet need, but the fiasco of torcetrapib will impede speedy launch of efficacious HDL-raising agents. It is likely to affect the physicians' confidence in all CETP inhibitors, and prolong their time to market.

The crowded antidyslipidemic market undergoing high genericization will make it challenging for the developmental compounds to secure a share of the market. The new compound will need to offer a major clinical advantage or a major cost benefit, in order to win a significant market share.

Read more...

• Obesity Drug Markets (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)

• Insomnia (21/05/2008)
• Fibromyalgia (21/05/2008)
• Canadian Generics Market (21/05/2008)
• Female Sexual Dysfunction (21/05/2008)
• Supportive Care in Oncology (21/05/2008)
• Irritable Bowel Syndrome (21/05/2008)
• Monoclonal Antibodies (21/05/2008)
• Depression (21/05/2008)
• Insomnia (21/05/2008)

---